Matrivax
Matrivax is a biotechnology company dedicated to developing innovative, clinically-impactful vaccines for the prevention and treatment of life-threatening infectious diseases. Based in Boston, MA, and funded by Morningside Investments, the company focuses on creating next-generation vaccines for diseases such as pneumococcal disease, Clostridioides difficile infection, typhoid fever, and others, utilizing proprietary technologies like PCMV.
Industries
Nr. of Employees
small (1-50)
Products
Pneumococcal vaccine candidate (recombinant pneumolysin-CbpA fusion protein)
A recombinant fusion protein antigen combining a genetically inactivated pneumolysin toxoid and conserved surface-protein epitopes designed to provide serotype-independent protection against Streptococcus pneumoniae.
C. difficile multivalent vaccine candidate (polysaccharide + toxoid targets)
A multivalent vaccine candidate targeting a conserved cell-surface polysaccharide (PSII) and toxins A and B to reduce bacterial colonization and neutralize toxin-mediated disease.
Typhoid vaccine candidate using protein capsular matrix approach
A typhoid fever vaccine candidate produced using protein capsular matrix vaccine chemistry intended to elicit seroconversion at reduced antigen dose compared with a licensed comparator.
Pneumococcal vaccine candidate (recombinant pneumolysin-CbpA fusion protein)
A recombinant fusion protein antigen combining a genetically inactivated pneumolysin toxoid and conserved surface-protein epitopes designed to provide serotype-independent protection against Streptococcus pneumoniae.
C. difficile multivalent vaccine candidate (polysaccharide + toxoid targets)
A multivalent vaccine candidate targeting a conserved cell-surface polysaccharide (PSII) and toxins A and B to reduce bacterial colonization and neutralize toxin-mediated disease.
Typhoid vaccine candidate using protein capsular matrix approach
A typhoid fever vaccine candidate produced using protein capsular matrix vaccine chemistry intended to elicit seroconversion at reduced antigen dose compared with a licensed comparator.
Expertise Areas
- Recombinant vaccine antigen design
- Protein toxoid development
- Polysaccharide-based vaccine technologies
- Preclinical animal models and challenge studies
Key Technologies
- Protein capsular matrix vaccine (PCMV) technology
- Recombinant fusion protein antigens
- Genetically inactivated toxoids
- Polysaccharide conjugate and conjugate-like immunogens